In Brief: Centocor's ReoPro

Executive Summary

Centocor's ReoPro: EPILOG trial halted due to positive interim results in 1,500 patients, Malvern, Penn.-based Centocor announces Dec. 15. The trial, which examined 30-day and six-month outcomes following percutaneous coronary intervention with ReoPro bolus plus 12-hour infusions given either with standard-dose or low-dose heparin in endpoints of death and myocardial infarction, was reviewed by an independent Safety and Efficacy Monitoring Committee, which recommended the trial be terminated because efficacy reached a p-value of <.0001. ReoPro is marketed for reduction of acute cardiac ischemic complications in patients undergoing angioplasty at high risk for abrupt artery closure...